Related Experiment Video

Updated: Aug 12, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Indole-3-carbinol activates the cyclin-dependent kinase inhibitor p15(INK4b) gene

Youichirou Matsuzaki1, Makoto Koyama, Toshiaki Hitomi

  • 1Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.

FEBS Letters
|October 12, 2004
PubMed

Insights

Indole-3-carbinol (I3C), found in broccoli, inhibits tumor cell growth by activating the p15INK4b gene. This specific activation of p15INK4b by I3C offers a new molecular target for cancer research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Indole-3-carbinol (I3C) is a natural compound from cruciferous vegetables.
  • I3C has demonstrated the ability to halt human tumor cell proliferation in the G1 phase.
  • The precise molecular mechanisms underlying I3C's anti-cancer effects remain incompletely understood.

Purpose of the Study:

  • To investigate the molecular mechanism by which Indole-3-carbinol (I3C) inhibits tumor cell growth.
  • To identify specific genes and pathways targeted by I3C in cancer cells.
  • To elucidate the role of cyclin-dependent kinase (CDK) inhibitors in I3C's anti-proliferative effects.

Main Methods:

  • Utilized HaCaT cells to study the effects of I3C treatment.
  • Analyzed gene expression changes, focusing on CDK inhibitors.
  • Investigated the activation of the p15INK4b gene promoter by I3C.

Main Results:

  • Indole-3-carbinol (I3C) treatment led to the activation of the p15INK4b gene via its promoter in HaCaT cells.
  • This activation was accompanied by significant inhibition of cell growth.
  • I3C treatment showed minimal impact on the expression of other CDK inhibitors, including p19INK4d, p21WAF1, and p27Kip1.

Conclusions:

  • The p15INK4b gene is identified as a key molecular target of Indole-3-carbinol (I3C).
  • I3C's anti-cancer activity is significantly mediated through the specific upregulation of p15INK4b.
  • These findings provide crucial insights into the mechanism of action of I3C as a potential anti-cancer agent.

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...